GAM
APLS

Gotham Asset Management’s Apellis Pharmaceuticals APLS Stock Holding History

Gotham Asset Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-78,750
Closed -$3.17M – 1800
2026
Q1 		$3.17M Sell
78,750
-89,705
-53% -$1.93M 0.01% 983
2025
Q4 		$4.23M Buy
168,455
+41,297
+32% +$969K 0.02% 851
2025
Q3 		$2.88M Buy
127,158
+7,929
+7% +$185K 0.01% 909
2025
Q2 		$2.06M Buy
119,229
+84,944
+248% +$1.57M 0.01% 922
2025
Q1 		$750K Buy
34,285
+9,986
+41% +$276K 0.01% 1092
2024
Q4 		$775K Buy
+24,299
New +$731K 0.01% 991
2024
Q2 		– Sell
-3,513
Closed -$206K – 1415
2024
Q1 		$206K Hold
3,513
– – ﹤0.01% 1285
2023
Q4 		$210K Buy
+3,513
New +$178K ﹤0.01% 1236
2023
Q3 		– Sell
-2,720
Closed -$248K – 1319
2023
Q2 		$248K Sell
2,720
-1,132
-29% -$97.7K 0.01% 1176
2023
Q1 		$254K Buy
+3,852
New +$222K 0.01% 1184
2022
Q4 		– Sell
-4,458
Closed -$304K – 1207
2022
Q3 		$304K Buy
+4,458
New +$264K 0.01% 973

Other funds holding APLS

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Gotham Asset Management's APLS Position: Q2 2026 in Review

Gotham Asset Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 78,750 shares — an estimated $3.17M sold.

Gotham Asset Management first reported a position in APLS in Q3 2022 and held it in 11 quarters. The position peaked at $4.23M in Q4 2025. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

  • Gotham Asset Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Gotham Asset Management sold 78,750 Apellis Pharmaceuticals shares in Q2 2026, an estimated $3.17M.
  • Gotham Asset Management first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 11 quarters.
  • Gotham Asset Management's Apellis Pharmaceuticals position peaked at $4.23M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.